Analgetic activity of the newly synthesized compound from the class of Hexaazaisowurtzitanes: in vivo research in nociceptive tests

Krylova SG, Kiseleva EA, Kulagina DA, et al. . Analgetic activity of the newly synthesized compound from the class of Hexaazaisowurtzitanes: in vivo research in nociceptive tests. Russian Journal of Pain. 2025;23(3):5‑10. (In Russ.)
https://doi.org/10.17116/pain2025230315

Подписка 2025 Российский журнал боли (Russian Journal of Pain)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To assess analgesic action of the newly patented compound from the class of hexaazaisowurzitanes as compared to tramadol in a battery of behavioral tests with various nociceptive systems.

MATERIAL AND METHODS

The experiments were performed in male mice of CD1 stock. A newly patented 4-(2-ethoxyacetyl)-2.6,8.10.12-pentaacetyl2.4,6.8,10.12hexaazatetracyclo [5.5,0.0^3.11.0^5.9]dodecane (M1) was administered daily through a probe at a dose 25—200 mg/kg. Tramadol was administered in a single dose 10 mg /kg for 1-3 days. The last injection was an hour before experimental manipulations. Analgesic effect was evaluated in a three-day administration on a model of chemical irritation of the peritoneum, in a single administration (test of central pain genesis “hot plate”) and mechanical paw compression (Randall-Selitto method).

RESULTS

Analysis of specific pharmacological activity in models of somatogenic pain (thermal, visceral pain, mechanical compression) revealed high analgesic activity of the newly synthesized compound 4-(2-ethoxyacetyl)-2.6,8.10.12-pentaacetyl 2.4,6.8,10.12 hexaazatetracyclo[5.5,0.0^3.11.0^5.9]dodecane (substance M1). The last one is comparable or exceeds the effect of tramadol. Analgesic effect of the new compound is realized at different levels of conduction and modulation of pain sensitivity.

CONCLUSION

The results of experimental tests with different nociception systems indicate advisability of further preclinical studies of the newly synthesized molecule with high analgesic therapeutic potential.

Keywords:

analgesic

hexaazaisowurzitane

behavioral tests

nociception

Authors:

Krylova S.G.

Tomsk National Research Medical Center

ORCID: 0000-0003-0249-1395

Kiseleva E.A.

Tomsk National Research Medical Center

ORCID: 0000-0003-3732-1302

Kulagina D.A.

Institute of Problems of Chemical and Energy Technologies

ORCID: 0000-0002-4673-5817

Povetyeva T.N.

Tomsk National Research Medical Center

ORCID: 0000-0001-8644-489X

Eremina V.V.

Institute of Problems of Chemical and Energy Technologies

ORCID: 0000-0002-1467-0051

Alekseeva N.A.

Institute of Problems of Chemical and Energy Technologies

ORCID: 0000-0002-1493-4125

Sysolyatin S.V.

Institute of Problems of Chemical and Energy Technologies

ORCID: 0000-0002-1405-171X

Zhdanov V.V.

Tomsk National Research Medical Center

ORCID: 0000-0002-9516-0204

Received:

26.11.2024

Accepted:

10.06.2025

Close metadata

References:

Mikhaylova AS. Clinician’s analgesic arsenal. Farmateka. 2018;(3):50-56. (In Russ.). https://doi.org/10.18565/pharmateca.2018.s3.50-56
Karateev AE, Nasonov EL, Ivashkin VT, Martynov AI, Yakhno NN, Arutyunov GP, Alekseeva LI, Abuzarova GR, Evseev MA, Kukushkin ML, Kopenkin SS, Lila AM, Lapina TL, Novikova DS, Popkova TV, Rebrov AP, Skorobogatykh KV, Chichasova NV. Rational use of non-steroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-prakticheskaya revmatologiya. 2018;56;1-29. (In Russ.). https://doi.org/10.14412/1995-4484-2018-1-29
The State Drug Guide of the Russian Federation. 2024. Accessed October 20, 2024. https://grls.rosminzdrav.ru/GRLS.aspx
Aguero S, Megy S, Eremina VV, Kalashnikov AI, Krylova SG, Kulagina DA, Lopatina KA, Fournier M, Povetyeva TN, Vorozhtsov AB, Sysolyatin SV, Zhdanov VV, Terreux R. Discovery of a Novel Non-Narcotic Analgesic Derived from the CL-20 Explosive: Synthesis, Pharmacology, and Target Identification of Thiowurtzine, a Potent Inhibitor of the Opioid Receptors and the Ion Channels. ACS Omega. 2021 May 31;6(23):15400-15411. PMID: 34151118; PMCID: PMC8210403. https://doi.org/10.1021/acsomega.1c01786
Kulagina DA, Sysolyatin SV, Krylova SG, Kiseleva EA, Povetyeva TN, Zueva EP, Eremina VV, Alekseeva NA, Strokova SV, Suslov NI, Zhdanov VV. Biological Activity of Hexaazaisowurtzitane Derivatives. Molecules. 2023 Dec 14;28(24):8084. PMID: 38138574; PMCID: PMC10745456. https://doi.org/10.3390/molecules28248084
RF Patent No. 2808905/05.12.2023, Bull. No. 34. Krylova SG; Povetyeva EN; Suslov NI; Zueva EP, Nesterova YuV, Afanasyeva OG, Kulpin PV, Kiseleva EA, Rybalkina OYu, Zhdanov VV, Baibakova OV, Eremina VV, Kulagina DA, Alekseeva NA, Chikina MV, Sysoluatin SV. 4-(2-Ethoxyacetyl)-2,6,8,10,12-Pentaacetyl-2,4,6,8,10,12-Hexaazaisowurtzitane as an Analgesic and Method for Its Preparation. (In Russ.). https://new.fips.ru/registers-doc-view/fips_servlet?DB=RUPAT&DocNumber=2023109790&TypeFile=html
Mironov AN. Preclinical Drug Research Guide. Moscow: Grif & K; 2013:944. (In Russ.).
Rice ASC, Cimino-Brown D, Eisenach JC, Kontinen VK, Lacroix-Fralish ML, Machin I, Mogil JS, Stöhr T; (on behalf of the Preclinical Pain Consortium). Animal models and the prediction of efficacy in clinical trials of analgesic drugs: a critical appraisal and call for uniform reporting standards. Pain. 2008 Oct 15;139(2):243-247. Epub 2008 Sept 23. PMID: 18814968. https://doi.org/10.1016/j.pain.2008.08.017
Barrot M. Tests and models of nociception and pain in rodents. Neuroscience. 2012;211:39-50. https://doi.org/10.1016/j.neuroscience.2011.12.041
Lemeshko BYu, Lemeshko SB. Problems of nonparametric goodness-of-fit test application in tasks of measurement results processing. Sistemy analiza i obrabotki dannykh. 2021;2(82):47-66. (In Russ.).